Apotex's Neulasta, Neupogen Biosimilars Clear Legal Hurdles, But Approval Questions Remain
Executive Summary
Federal appeals court affirms ruling that Apotex's biosimilars do not infringe Amgen's manufacturing process patent, but its applications have stalled at FDA for the past three years.